15:18 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

China FDA approves IND for Canbridge's GBM candidate

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved an IND to begin a Phase II/III trial of asunercept (APG101, CAN-008) to treat glioblastoma multiforme (GBM). A spokesperson told BioCentury that Canbridge plans to...
01:13 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest FASL inhibitors could help treat immunotherapy-resistant melanoma. In a mouse model of immunotherapy-resistant melanoma, a fusion protein consisting of Fas receptor and the Fc region of murine IgG2A (Fas-Fc) that...
23:17 , Sep 29, 2017 |  BioCentury  |  Strategy

Bridge to innovation

While Zai Lab Ltd. has joined the ranks of Chinese biotechs making a splash on NASDAQ, less noticed may be the first wave of China-based players moving into Boston to jump-start their push into novel...
23:16 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Apogenix's asunercept receives PRIME designation for glioblastoma

In late May, Apogenix AG (Heidelberg, Germany) said EMA granted PRIority MEdicines (PRIME) designation to asunercept (APG101, CAN-008) to treat glioblastoma. The designation is based on data from a Phase II trial in which asunercept...
22:03 , May 23, 2017 |  BC Extra  |  Financial News

Lapam leads Canbridge's $25M series B

Canbridge Life Sciences Ltd. (Beijing, China) raised $25 million in a series B led by Lapam Capital. Also participating were Qiming Venture Partners, Yuanming Capital, Yanyuan Capital, Biossom Investment Management and WuXi AppTec Co. Ltd....
23:51 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture studies suggest activation of CD95 in combination with KRAS or HDAC inhibition could treat KRAS-expressing non-small cell lung cancer (NSCLC). In a human NSCLC cell line harboring an oncogenic KRAS...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

APG101: Phase I/II started

Canbridge began a Taiwanese Phase I/II trial to evaluate once-weekly 200 and 400 mg IV CAN-008 plus temozolomide in about 55 patients with newly diagnosed GBM. The trial comprises an open-label, dose-escalation Phase I portion...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

APG101: Phase I/II start

This month, Canbridge will begin a Phase I/II trial evaluating CAN-008 plus temozolomide in about 55 patients. The trial comprises an open-label, dose-escalation Phase I portion and a double-blind, placebo-controlled Phase II portion. Canbridge has...
07:00 , Aug 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: FAS receptor (CD95); CD95 ligand

Autoimmune disease INDICATION: Systemic lupus erythematosus (SLE) Patient sample and mouse studies suggest inhibitors of CD95-mediated calcium signaling could help treat SLE. In patient serum and skin samples, levels of soluble CD95 ligand were higher...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-125b-5p (miR-125b-5p)

Hepatic disease INDICATION: Liver failure Patient sample, cell culture and mouse studies suggest miR-125b-5p could help treat acute liver failure caused by acetaminophen and other toxins. In liver tissue samples, miR-125b-5p levels were lower in...